Covered recipient · General Payments record
SURAJ MULEY
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$249,067.84
278 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $163,722.50 | 57 |
| Consulting Fee | $32,400.00 | 7 |
| Travel and Lodging | $31,484.17 | 110 |
| Honoraria | $13,900.00 | 5 |
| Food and Beverage | $7,561.17 | 99 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| CSL Behring | $73,648.36 | 82 |
| Alexion Pharmaceuticals, Inc. | $68,627.09 | 57 |
| ARGENX US, INC. | $45,611.15 | 52 |
| Takeda Pharmaceuticals U.S.A., Inc. | $29,465.26 | 33 |
| CATALYST PHARMACEUTICALS, INC. | $11,559.03 | 13 |
| Grifols USA, LLC | $7,335.50 | 9 |
| UCB, Inc. | $6,433.74 | 11 |
| Horizon Therapeutics plc | $4,355.67 | 8 |
| Janssen Global Services, LLC | $687.90 | 1 |
| Biogen, Inc. | $467.40 | 4 |
| Celgene Corporation | $340.73 | 3 |
| Genentech, Inc. | $281.67 | 3 |
| Grifols Shared Services North America, Inc. | $137.39 | 1 |
| EMD Serono, Inc. | $116.95 | 1 |
Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SURAJ MULEY
NPI 1417056730 · CMS profile ID 64124
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
PHOENIX, AZ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1417056730?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SURAJ MULEY, NPI 1417056730, CMS profile ID 64124. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417056730?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). SURAJ MULEY, NPI 1417056730, CMS profile ID 64124. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417056730?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- SURAJ MULEY, NPI 1417056730, CMS profile ID 64124, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1417056730?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
278 matching records · $249,067.84 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 278.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Grifols USA, LLC | $428.08 | 11/02/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965229541 | CMS |
| Alexion Pharmaceuticals, Inc. | $1,020.00 | 11/01/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915628449 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,250.00 | 10/28/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955745683 | CMS |
| ARGENX US, INC. | $677.09 | 10/27/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951631595 | CMS |
| ARGENX US, INC. | $247.90 | 10/27/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951631597 | CMS |
| Alexion Pharmaceuticals, Inc. | $2,550.00 | 10/27/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915598609 | CMS |
| ARGENX US, INC. | $612.20 | 10/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951631591 | CMS |
| ARGENX US, INC. | $281.40 | 10/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951631593 | CMS |
| Alexion Pharmaceuticals, Inc. | $96.14 | 10/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915827303 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $43.79 | 10/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955745655 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $70.34 | 10/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955745659 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $33.63 | 10/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955745663 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $12.57 | 10/21/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955745667 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.94 | 10/21/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955745671 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $10.63 | 10/21/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955745673 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $59.00 | 10/21/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955745679 | CMS |
| Alexion Pharmaceuticals, Inc. | $131.69 | 10/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915323165 | CMS |
| Grifols USA, LLC | $387.50 | 10/19/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965229537 | CMS |
| Grifols USA, LLC | $18.31 | 10/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918701753 | CMS |
| Grifols USA, LLC | $108.08 | 10/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918724525 | CMS |
| ARGENX US, INC. | $5,750.00 | 10/14/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951631545 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $30.00 | 10/12/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955745639 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $12.50 | 10/12/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955745643 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $15.61 | 10/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955745647 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $2.68 | 10/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955745651 | CMS |
| Horizon Therapeutics plc | $47.92 | 10/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937664255 | CMS |
| Horizon Therapeutics plc | $23.96 | 10/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937664257 | CMS |
| Horizon Therapeutics plc | $62.29 | 10/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937664259 | CMS |
| Horizon Therapeutics plc | $23.96 | 10/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937664261 | CMS |
| Horizon Therapeutics plc | $12.50 | 10/08/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937664263 | CMS |
| Horizon Therapeutics plc | $4,000.00 | 10/08/2022 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937664265 | CMS |
| Alexion Pharmaceuticals, Inc. | $130.25 | 10/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914746701 | CMS |
| Horizon Therapeutics plc | $110.29 | 10/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937664253 | CMS |
| Alexion Pharmaceuticals, Inc. | $2,550.00 | 10/06/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915033097 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,750.00 | 10/06/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955745635 | CMS |
| Alexion Pharmaceuticals, Inc. | $91.13 | 10/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915649033 | CMS |
| CSL Behring | $2,970.00 | 10/04/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940838157 | CMS |
| CSL Behring | $5.63 | 10/04/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940838159 | CMS |
| Celgene Corporation | $105.63 | 10/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932490857 | CMS |
| ARGENX US, INC. | $26.43 | 09/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951631675 | CMS |
| ARGENX US, INC. | $22.50 | 09/30/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951631679 | CMS |
| ARGENX US, INC. | $2,000.00 | 09/30/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951631683 | CMS |
| ARGENX US, INC. | $89.92 | 09/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951631677 | CMS |
| ARGENX US, INC. | $22.50 | 09/28/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951631681 | CMS |
| ARGENX US, INC. | $2,000.00 | 09/28/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951631685 | CMS |
| Alexion Pharmaceuticals, Inc. | $22.66 | 09/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914968097 | CMS |
| CSL Behring | $102.71 | 09/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940838155 | CMS |
| Biogen, Inc. | $82.29 | 09/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923386965 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $95.54 | 09/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955745631 | CMS |
| CSL Behring | $4,620.00 | 09/23/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940838153 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $638,715.37 | 30 |
| PY2024 | Principal investigator | $54,903.49 | 3 |
| PY2023 | Principal investigator | $29,152.25 | 2 |
| PY2022 | Principal investigator | $17,302.50 | 3 |
| PY2021 | Principal investigator | $189,151.70 | 32 |
| PY2020 | Principal investigator | $78,931.56 | 14 |
| PY2019 | Recipient | $17,955.00 | 1 |
| PY2019 | Principal investigator | $64,325.84 | 10 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
30 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | GENZYME CORPORATION | $1,500.00 | 12/08/2025 | Covered Recipient Teaching Hospital Honorhealth Scottsdale Osborn Med Ct | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136132 |
| Principal investigator 1 | ARGENX US, INC. | $15.66 | 12/01/2025 | Covered Recipient Teaching Hospital Honorhealth Scottsdale Thompson Peak | A randomized, double-blinded, placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of efgartigimod PH20 SC administered by prefilled syringe in adult participants with ocular myasthenia gravis | No dispute reported | 06/30/2026 | 1237142340 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $369,837.37 | 11/19/2025 | Non-covered Recipient Entity HONOR HEALTH RESEARCH INSTITUTE | A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension phase | No dispute reported | 06/30/2026 | 1190309330 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $11,495.86 | 11/06/2025 | Non-covered Recipient Entity HONOR HEALTH RESEARCH INSTITUTE | A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase | No dispute reported | 06/30/2026 | 1190309332 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $158,319.18 | 11/01/2025 | Non-covered Recipient Entity HONOR HEALTH RESEARCH INSTITUTE | A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension phase | No dispute reported | 06/30/2026 | 1190312211 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,150.00 | 10/22/2025 | Non-covered Recipient Entity HONOR HEALTH RESEARCH INSTITUTE | A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase | No dispute reported | 06/30/2026 | 1190312217 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $100.00 | 10/14/2025 | Covered Recipient Teaching Hospital Methodist Hospital Of Sacramento | Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies | No dispute reported | 06/30/2026 | 1185552409 |
| Principal investigator 1 | ARGENX US, INC. | $2,330.40 | 09/10/2025 | Covered Recipient Teaching Hospital Honorhealth Scottsdale Thompson Peak | A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). | No dispute reported | 06/30/2026 | 1237142264 |
| Principal investigator 1 | ARGENX US, INC. | $1,068.20 | 09/10/2025 | Covered Recipient Teaching Hospital Honorhealth Scottsdale Thompson Peak | A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). | No dispute reported | 06/30/2026 | 1237142268 |
| Principal investigator 1 | ARGENX US, INC. | $3,128.40 | 09/03/2025 | Covered Recipient Teaching Hospital Honorhealth Scottsdale Thompson Peak | A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). | No dispute reported | 06/30/2026 | 1237142245 |
| Principal investigator 1 | ARGENX US, INC. | $2,100.00 | 09/03/2025 | Covered Recipient Teaching Hospital Honorhealth Scottsdale Thompson Peak | A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). | No dispute reported | 06/30/2026 | 1237142253 |
| Principal investigator 1 | ARGENX US, INC. | $1,500.00 | 09/03/2025 | Covered Recipient Teaching Hospital Honorhealth Scottsdale Thompson Peak | A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). | No dispute reported | 06/30/2026 | 1237142257 |
| Principal investigator 1 | ARGENX US, INC. | $2,000.00 | 09/03/2025 | Covered Recipient Teaching Hospital Honorhealth Scottsdale Thompson Peak | A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). | No dispute reported | 06/30/2026 | 1237142261 |
| Principal investigator 1 | ARGENX US, INC. | $131.30 | 08/27/2025 | Covered Recipient Teaching Hospital Honorhealth Scottsdale Thompson Peak | A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). | No dispute reported | 06/30/2026 | 1237142250 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,000.00 | 08/25/2025 | Covered Recipient Teaching Hospital Honorhealth Scottsdale Osborn Med Ct | PHASE 3 Study in Standard of Care Treated Patients with CIDP (Placebo & IVIG comparator) | No dispute reported | 06/30/2026 | 1226136082 |
| Principal investigator 1 | ARGENX US, INC. | $3,000.00 | 07/16/2025 | Covered Recipient Teaching Hospital Honorhealth Scottsdale Thompson Peak | A randomized, double-blinded, placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of efgartigimod PH20 SC administered by prefilled syringe in adult participants with ocular myasthenia gravis | No dispute reported | 06/30/2026 | 1237142330 |
| Principal investigator 1 | ARGENX US, INC. | $12,000.00 | 07/16/2025 | Covered Recipient Teaching Hospital Honorhealth Scottsdale Thompson Peak | A randomized, double-blinded, placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of efgartigimod PH20 SC administered by prefilled syringe in adult participants with ocular myasthenia gravis | No dispute reported | 06/30/2026 | 1237142335 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $135.00 | 07/01/2025 | Covered Recipient Teaching Hospital HONORHEALTH SCOTTSDALE OSBORN MED CT | A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223266783 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $17,447.00 | 06/24/2025 | Covered Recipient Teaching Hospital HONORHEALTH DEER VALLEY MED CTR | A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223266771 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,120.00 | 06/24/2025 | Covered Recipient Teaching Hospital HONORHEALTH DEER VALLEY MED CTR | A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223266773 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,052.00 | 06/24/2025 | Covered Recipient Teaching Hospital HONORHEALTH DEER VALLEY MED CTR | A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223266775 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,312.00 | 06/01/2025 | Covered Recipient Teaching Hospital HONORHEALTH SCOTTSDALE OSBORN MED CT | A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223266781 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,312.00 | 04/01/2025 | Covered Recipient Teaching Hospital HONORHEALTH SCOTTSDALE OSBORN MED CT | A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223266777 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $135.00 | 04/01/2025 | Covered Recipient Teaching Hospital HONORHEALTH SCOTTSDALE OSBORN MED CT | A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223266779 |
| Principal investigator 1 | ARGENX US, INC. | $1,000.00 | 03/07/2025 | Covered Recipient Teaching Hospital Honorhealth Scottsdale Thompson Peak | A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). | No dispute reported | 06/30/2026 | 1237142277 |
| Principal investigator 1 | ARGENX US, INC. | $12,000.00 | 03/07/2025 | Covered Recipient Teaching Hospital Honorhealth Scottsdale Thompson Peak | A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). | No dispute reported | 06/30/2026 | 1237142282 |
| Principal investigator 1 | ARGENX US, INC. | $1,323.00 | 03/07/2025 | Covered Recipient Teaching Hospital Honorhealth Scottsdale Thompson Peak | A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). | No dispute reported | 06/30/2026 | 1237142287 |
| Principal investigator 1 | ARGENX US, INC. | $8,142.40 | 03/07/2025 | Covered Recipient Teaching Hospital Honorhealth Scottsdale Thompson Peak | A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). | No dispute reported | 06/30/2026 | 1237142290 |
| Principal investigator 1 | ARGENX US, INC. | $2,250.00 | 03/07/2025 | Covered Recipient Teaching Hospital Honorhealth Scottsdale Thompson Peak | A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). | No dispute reported | 06/30/2026 | 1237142295 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $19,810.60 | 01/31/2025 | Non-covered Recipient Entity HONOR HEALTH RESEARCH INSTITUTE | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190312213 |